December 21, 2017 / 12:19 PM / in 6 months

BRIEF-Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders

Dec 21 (Reuters) - Ionis Pharmaceuticals Inc:

* IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

* IONIS PHARMACEUTICALS- UNDER AGREEMENT WITH JANSSEN, CO TO RECEIVE NEARLY $585 MILLION IN DEVELOPMENT, REGULATORY, SALES MILESTONE PAYMENTS & LICENSE FEES

* IONIS PHARMACEUTICALS INC - EARNED $5 MILLION MILESTONE PAYMENT ASSOCIATED WITH INITIATION, ENROLLMENT IN PHASE 1 CLINICAL STUDY OF IONIS-JBI1-2.5(RX)

* IONIS PHARMACEUTICALS INC - JANSSEN BIOTECH IS CONDUCTING PHASE 1 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below